AAV9 gene replacement therapy for respiratory insufficiency in very‐long chain acyl‐CoA dehydrogenase deficiency
Authors:
- 17 April 2019
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 42 (5) , 870-877
Abstract
Very‐long chain acyl‐CoA dehydrogenase (VLCAD) deficiency (VLCADD) is an autosomal recessive disorder of fatty acid oxidation. Fatty acids are a major source of energy during catabolic stress, so the absence of VLCAD can result in a metabolic crises and respiratory insufficiency. The etiology of this respiratory insufficiency is unclear. Thus, our aims were: (1) to characterize respiratory pathophysiology in VLCADD mice (VLCAD−/−), and (2) to determine if AAV9‐mediated gene therapy improves respiratory function. For the first aim, VLCAD−/− and wild‐type (WT) mice underwent an exercise/fast “stress protocol” and awake spontaneous breathing was evaluated using whole‐body plethysmography (WBP) both at baseline and during a hypercapnic respiratory challenge (FiO2: 0.21; FiCO2: 0.07; nitrogen balance). During hypercapnia, VLCAD −/− mice had a significantly lower frequency, tidal volume, minute ventilation, and peak inspiratory and expiratory flow, all of which indicate respiratory insufficiency. Histologically, the cardiac and respiratory muscles of stressed VLCAD −/− animals had an accumulation of intramyocellular lipids. For the second aim, a single systemic injection of AAV9‐VLCAD gene therapy improved this respiratory pathology by normalizing breathing frequency and enhancing peak inspiratory flow. In addition, following gene therapy, there was a moderate reduction of lipid accumulation in the respiratory muscles. Furthermore, VLCAD protein expression was robust in cardiac and respiratory muscle. This was confirmed by immuno‐staining with anti‐human VLCAD antibody. In summary, stress with exercise and fasting induces respiratory insufficiency in VLCAD−/− mice and a single injection with AAV9‐VLCAD gene therapy ameliorates breathing.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K08HD077040)
- National Heart, Lung, and Blood Institute (P01HL131471)
- National Institute of Neurological Disorders and Stroke (R21NS098131)
This publication has 23 references indexed in Scilit:
- Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiencyJournal of Human Genetics, 2018
- Infants suspected to have very-long chain acyl-CoA dehydrogenase deficiency from newborn screeningMolecular Genetics and Metabolism, 2014
- Cardiac-specific VLCAD deficiency induces dilated cardiomyopathy and cold intoleranceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2014
- VLCAD deficiency in a patient who recovered from ventricular fibrillation, but died suddenly of a respiratory syncytial virus infectionPediatrics International, 2013
- Long-term Correction of Very Long-chain Acyl-CoA Dehydrogenase Deficiency in Mice Using AAV9 Gene TherapyMolecular Therapy, 2012
- Very long-chain acyl-CoA dehydrogenase deficiency presenting as acute hypercapnic respiratory failureEuropean Respiratory Journal, 2006
- Abnormal mitochondrial bioenergetics and heart rate dysfunction in mice lacking very-long-chain acyl-CoA dehydrogenaseAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Clinical and molecular heterogeneity in very–long-chain acyl-coenzyme a dehydrogenase deficiencyPediatric Neurology, 2000
- Disorders of mitochondrial fatty acyl‐CoA β‐oxidationJournal of Inherited Metabolic Disease, 1999
- Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patientsClinica Chimica Acta, 1998